Dr Reddy’s Labs Announces Commercial Launch Of Covid19 Drug 2-DG, MRP Of Each Sachet Fixed At ₹990

Dr Reddy’s Laboratories has announced the commercial launch of 2-deoxy-D-glucose (2-DG), a drug for moderate to severe Covid-19 patients administered as an adjunct therapy to the existing standard care.

2-DG was developed by the Institute of Nuclear Medicine & Allied Sciences (INMAS), a laboratory of the Defence Research and Development Organisation (DRDO), in collaboration with Dr. Reddy’s Labs.

The emergency use approval for anti-Covid-19 therapeutic application of the drug was granted on May 1, 2021.

2-DG manufactured by Dr Reddy’s has a purity of 99.5 per cent and is being sold commercially under the brand name 2DGTM. The maximum retail price (MRP) of each sachet has been fixed at ₹990, with a subsidised rate offered to government institutions.

Dr Reddy’s will supply to major government as well as private hospitals across India. In the initial weeks, the company will make the drug available in hospitals across metros and Tier 1 cities, and subsequently expand coverage to the rest of India.

The oral drug can be administered only upon prescription and under the supervision of a qualified physician to hospitalised patients.

Also Read -DRDO Developed '2-DG' Drug Inhibits Coronavirus Multiplication, Likely To Work Against All COVID Variants: Study